129 related articles for article (PubMed ID: 32889748)
61. Quercetin and non-alcoholic fatty liver disease: A review based on experimental data and bioinformatic analysis.
Chen L; Liu J; Mei G; Chen H; Peng S; Zhao Y; Yao P; Tang Y
Food Chem Toxicol; 2021 Aug; 154():112314. PubMed ID: 34087406
[TBL] [Abstract][Full Text] [Related]
62. Phloroglucinol Strengthens the Antioxidant Barrier and Reduces Oxidative/Nitrosative Stress in Nonalcoholic Fatty Liver Disease (NAFLD).
Drygalski K; Siewko K; Chomentowski A; Odrzygóźdź C; Zalewska A; Krętowski A; Maciejczyk M
Oxid Med Cell Longev; 2021; 2021():8872702. PubMed ID: 33510844
[TBL] [Abstract][Full Text] [Related]
63. Frataxin-Mediated PINK1-Parkin-Dependent Mitophagy in Hepatic Steatosis: The Protective Effects of Quercetin.
Liu P; Lin H; Xu Y; Zhou F; Wang J; Liu J; Zhu X; Guo X; Tang Y; Yao P
Mol Nutr Food Res; 2018 Aug; 62(16):e1800164. PubMed ID: 29935106
[TBL] [Abstract][Full Text] [Related]
64. Hepatic autophagy fluctuates during the development of non-alcoholic fatty liver disease.
Ding H; Ge G; Tseng Y; Ma Y; Zhang J; Liu J
Ann Hepatol; 2020; 19(5):516-522. PubMed ID: 32553647
[TBL] [Abstract][Full Text] [Related]
65. Hepatic AMP Kinase as a Potential Target for Treating Nonalcoholic Fatty Liver Disease: Evidence from Studies of Natural Products.
Xu G; Huang K; Zhou J
Curr Med Chem; 2018; 25(8):889-907. PubMed ID: 28393690
[TBL] [Abstract][Full Text] [Related]
66. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M
BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892
[TBL] [Abstract][Full Text] [Related]
67. Quercetin ameliorate insulin resistance and up-regulates cellular antioxidants during oleic acid induced hepatic steatosis in HepG2 cells.
Vidyashankar S; Sandeep Varma R; Patki PS
Toxicol In Vitro; 2013 Mar; 27(2):945-53. PubMed ID: 23348005
[TBL] [Abstract][Full Text] [Related]
68. Liver delipidating effect of a combination of resveratrol and quercetin in rats fed an obesogenic diet.
Arias N; Macarulla MT; Aguirre L; Miranda J; Portillo MP
J Physiol Biochem; 2015 Sep; 71(3):569-76. PubMed ID: 25827944
[TBL] [Abstract][Full Text] [Related]
69. Models of non-Alcoholic Fatty Liver Disease and Potential Translational Value: the Effects of 3,5-L-diiodothyronine.
Grasselli E; Canesi L; Portincasa P; Voci A; Vergani L; Demori I
Ann Hepatol; 2017; 16(5):707-719. PubMed ID: 28809727
[TBL] [Abstract][Full Text] [Related]
70. Peroxiredoxin 5 ameliorates obesity-induced non-alcoholic fatty liver disease through the regulation of oxidative stress and AMP-activated protein kinase signaling.
Kim MH; Seong JB; Huh JW; Bae YC; Lee HS; Lee DS
Redox Biol; 2020 Jan; 28():101315. PubMed ID: 31505325
[TBL] [Abstract][Full Text] [Related]
71. Fisetin Protects Against Hepatic Steatosis Through Regulation of the Sirt1/AMPK and Fatty Acid β-Oxidation Signaling Pathway in High-Fat Diet-Induced Obese Mice.
Liou CJ; Wei CH; Chen YL; Cheng CY; Wang CL; Huang WC
Cell Physiol Biochem; 2018; 49(5):1870-1884. PubMed ID: 30235452
[TBL] [Abstract][Full Text] [Related]
72. Upregulation of miR-125b by estrogen protects against non-alcoholic fatty liver in female mice.
Zhang ZC; Liu Y; Xiao LL; Li SF; Jiang JH; Zhao Y; Qian SW; Tang QQ; Li X
J Hepatol; 2015 Dec; 63(6):1466-75. PubMed ID: 26272872
[TBL] [Abstract][Full Text] [Related]
73. The role of hepassocin in the development of non-alcoholic fatty liver disease.
Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
[TBL] [Abstract][Full Text] [Related]
74. Pioglitazone, quercetin and hydroxy citric acid effect on cytochrome P450 2E1 (CYP2E1) enzyme levels in experimentally induced non alcoholic steatohepatitis (NASH).
Surapaneni KM; Priya VV; Mallika J
Eur Rev Med Pharmacol Sci; 2014; 18(18):2736-41. PubMed ID: 25317811
[TBL] [Abstract][Full Text] [Related]
75. Artemisia capillaris formula inhibits hepatic steatosis via an miR‑122‑induced decrease in fatty acid synthase expression in vivo and in vitro.
Liu L; Zhao J; Li Y; Wan Y; Lin J; Shen A; Xu W; Li H; Zhang Y; Xu J; Peng J; Hong Z
Mol Med Rep; 2016 Jun; 13(6):4751-8. PubMed ID: 27081834
[TBL] [Abstract][Full Text] [Related]
76. Quercetin administration post-weaning attenuates high-fructose, high-cholesterol diet-induced hepatic steatosis in growing, female, Sprague Dawley rat pups.
Donaldson J; Ngema M; Nkomozepi P; Erlwanger K
J Sci Food Agric; 2019 Dec; 99(15):6954-6961. PubMed ID: 31414497
[TBL] [Abstract][Full Text] [Related]
77. Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice.
Takahara I; Akazawa Y; Tabuchi M; Matsuda K; Miyaaki H; Kido Y; Kanda Y; Taura N; Ohnita K; Takeshima F; Sakai Y; Eguchi S; Nakashima M; Nakao K
PLoS One; 2017; 12(3):e0170591. PubMed ID: 28278289
[TBL] [Abstract][Full Text] [Related]
78. Effect of a high fat, high sucrose diet on the promotion of non-alcoholic fatty liver disease in male rats: the ameliorative role of three natural compounds.
Ragab SM; Abd Elghaffar SKh; El-Metwally TH; Badr G; Mahmoud MH; Omar HM
Lipids Health Dis; 2015 Jul; 14():83. PubMed ID: 26228038
[TBL] [Abstract][Full Text] [Related]
79. The beneficial effects of resveratrol on steatosis and mitochondrial oxidative stress in HepG2 cells.
Izdebska M; Piątkowska-Chmiel I; Korolczuk A; Herbet M; Gawrońska-Grzywacz M; Gieroba R; Sysa M; Czajkowska-Bania K; Cygal M; Korga A; Dudka J
Can J Physiol Pharmacol; 2017 Dec; 95(12):1442-1453. PubMed ID: 28759727
[TBL] [Abstract][Full Text] [Related]
80. Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease.
Li X; Wang Z; Klaunig JE
Toxicology; 2018 Dec; 410():199-213. PubMed ID: 30120929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
